Trial Profile
A Multicenter, Open-Label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Intravenous Brivaracetam in Subjects ≥ 1 Month < 16 Years of Age With Epilepsy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Feb 2022
Price :
$35
*
At a glance
- Drugs Brivaracetam (Primary) ; Brivaracetam (Primary)
- Indications Epilepsy
- Focus Adverse reactions; Pharmacokinetics
- Sponsors UCB Biopharma
- 23 Feb 2022 Results published in the Epilepsia
- 01 Sep 2021 Results presented at the 34th International Epilepsy Congress
- 16 Nov 2020 Status changed from active, no longer recruiting to completed.